News ArchivesRead News

Breakthrough technology for testing Alzheimer’s and Parkinson’s drugs

Thursday February 18, 2010

news@Northwestern - In a breakthrough development for early drug research, Northeastern University scientists are now able to test, in real time, the impact of new drugs being developed to treat neurodegenerative diseases like Alzheimer’s and Parkinson’s.

A patented new imaging technology developed by Northeastern’s Center for Translational NeuroImaging (CTNI) enables researchers to produce highly accurate data without resorting to traditional preclinical testing methods. Those methods involve euthanizing laboratory animals at different stages of the study to assess disease progression and the effectiveness of the drug.

“Animal imaging is crucial in early drug discovery, but the use of anesthesia creates an artificial situation that can mask true drug activity,” said Craig Ferris, CTNI director and professor of psychology and pharmaceutical sciences. “Studying awake animals leads to improved drug safety evaluations and data accuracy.”

Ferris noted the testing they are now able to perform at CTNI maximizes accuracy and leads to improved drug development processes for pharmaceutical and biotechnology companies that are working to treat central nervous system diseases, including Alzheimer’s and Parkinson’s diseases.

The center’s imaging-based preclinical testing is performed under the aegis of a new business venture, called Ekam Imaging, Inc., founded by a team that includes Ferris and Graham Jones, professor and chair of the department of chemistry and chemical biology at Northeastern.

The technology has spawned eight patents focused on the imaging of animals and a new method for tagging drugs using microwave-mediated organic synthesis technology. This procedure allows injected compounds to be more accurately tracked and evaluated for efficacy.

Additionally, the center uses advanced data-analysis techniques, including three-dimensional brain “atlases” used for data visualization, and imaging models of various disease conditions.

“The advantages of our technology give researchers the ability to provide information and analysis to drug companies that enable them to make more informed go/no-go decisions on their drug development programs,” added Ferris. “It will help reduce the time to market for new therapeutics and lower the overall cost of drug development.”

Recent News

Nov 22 - A caregiver's story: Living and loving through the slow process of dying
Nov 19 - Testosterone cause of sex differences in the occurrence of Parkinson’s disease, new research suggests
Nov 18 - New strategy reduces side effects in Parkinson's treatment
Nov 14 - Opinion: The never-ending tests of Parkinson's disease
Nov 13 - Parkinson’s disease: A new tool for diagnosis
Nov 10 - Parkinson's Disease Drug May Be Useful For Delaying, Preventing Blindness In Older Population
Nov 9 - Microsoft VP’s diagnosis fuels employees’ heartfelt efforts to help others
Nov 6 - Lewy body dementia: unrecognized and misdiagnosed
Nov 5 - Gait difficulties in Parkinson's linked to new blood vessels in brain
Oct 30 - Special Section: Enabling Technologies for Parkinson’s Disease Management
Oct 27 - Scientists discover a 'switchboard' of molecules that protect against Parkinson's disease
Oct 26 - Dancing improves mobility and quality of life in people with Parkinson's
Oct 23 - The amazing woman who can smell Parkinson’s disease — before symptoms appear
Oct 20 - Personal Essay: The deviousness of dementia
Oct 19 - Mechanism that 'melts' protein clumps may lead to new Parkinson's treatments
Oct 19 - Researchers find that stem cell treatment may reduce cognitive impairment related to dementia with Lewy bodies
Oct 17 - Cancer Drug Helps Parkinson's Patients
Oct 12 - Researchers identify immune gene that can prevent Parkinson's disease and dementia
Oct 12 - Blog Post: An Alert, Well-Hydrated Artist in No Acute Distress
Oct 7 - This month, a brain surgery will be broadcast on live TV for the first time ever